Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299344 | 0.91 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1KDM4EALDH1A1MBTD1 | |
| SCHEMBL30299269 | 0.78 | MEN1 (0.45) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL30299354 | 0.76 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1KDM4EALDH1A1MBTD1 | |
| SCHEMBL30299374 | 0.75 | SMN1; SMN2 (0.35) | KDM4E | |
| SCHEMBL1710098 | 0.74 | L3MBTL3 (0.73) | L3MBTL3L3MBTL1KDM4EPOLBALDH1A1 | |
| SCHEMBL30299283 | 0.74 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL30090685 | 0.73 | SLC18A3 (0.39) | — | |
| SCHEMBL30299369 | 0.73 | AXL (0.37) | KDM4EALDH1A1HRH3 | |
| SCHEMBL30090687 | 0.72 | AXL (0.38) | KDM4EALDH1A1 | |
| SCHEMBL30299373 | 0.72 | HRH3 (0.37) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | disclosed |